-
1
-
-
70349256226
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
-
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
-
(2009)
Blood
, vol.114
, Issue.5
, pp. 937-951
-
-
Vardiman, J.W.1
Thiele, J.2
Arber, D.A.3
-
2
-
-
39149105615
-
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment [6]
-
DOI 10.1038/sj.leu.2404914, PII 2404914
-
Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438. (Pubitemid 351250553)
-
(2008)
Leukemia
, vol.22
, Issue.2
, pp. 437-438
-
-
Barosi, G.1
Mesa, R.A.2
Thiele, J.3
Cervantes, F.4
Campbell, P.J.5
Verstovsek, S.6
Dupriez, B.7
Levine, R.L.8
Passamonti, F.9
Gotlib, J.10
Reilly, J.T.11
Vannucchi, A.M.12
Hanson, C.A.13
Solberg, L.A.14
Orazi, A.15
Tefferi, A.16
-
3
-
-
34447610836
-
Zwei Falle von Leukamie mit eigenthumlichem Blutresp. Knochenmarksbefund
-
Heuck G. Zwei Falle von Leukamie mit eigenthumlichem Blutresp. Knochenmarksbefund [Two cases of leukemia with peculiar blood and bone marrow findings, respectively]. Arch Pathol Anat Physiol Virchows. 1879;78:475-496.
-
(1879)
Arch Pathol Anat Physiol Virchows
, vol.78
, pp. 475-496
-
-
Heuck, G.1
-
4
-
-
0001639195
-
Some speculations on the myeloproliferative syndromes
-
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
-
(1951)
Blood
, vol.6
, pp. 372-375
-
-
Dameshek, W.1
-
5
-
-
0017812507
-
Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis
-
Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51(2):189-194. (Pubitemid 8284647)
-
(1978)
Blood
, vol.51
, Issue.2
, pp. 189-194
-
-
Jacobson, R.J.1
Salo, A.2
Fialkow, P.J.3
-
6
-
-
38349060667
-
The history of myeloproliferative disorders: Before and after Dameshek
-
Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008;22(1):3-13.
-
(2008)
Leukemia
, vol.22
, Issue.1
, pp. 3-13
-
-
Tefferi, A.1
-
7
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
-
DOI 10.1038/nature03546
-
James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
-
(2005)
Nature
, vol.434
, Issue.7037
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Le, C.J.-P.3
Staerk, J.4
Delhommeau, F.5
Lacout, C.6
Garcon, L.7
Raslova, H.8
Berger, R.9
Bennaceur-Griscelli, A.10
Villeval, J.L.11
Constantinescu, S.N.12
Casadevall, N.13
Vainchenker, W.14
-
9
-
-
72849159485
-
Chromosome studies on normal and leukemic human leukocytes
-
July
-
Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960 July; 25:85-109.
-
(1960)
J Natl Cancer Inst
, vol.25
, pp. 85-109
-
-
Nowell, P.C.1
Hungerford, D.A.2
-
10
-
-
0021802841
-
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
-
DOI 10.1038/315550a0
-
Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550-554. (Pubitemid 15021190)
-
(1985)
Nature
, vol.315
, Issue.6020
, pp. 550-554
-
-
Shtivelman, E.1
Lifshitz, B.2
Gale, R.P.3
Canaani, E.4
-
11
-
-
0022352068
-
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome
-
Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med. 1985;313(23):1429-1433. (Pubitemid 16212323)
-
(1985)
New England Journal of Medicine
, vol.313
, Issue.23
, pp. 1429-1433
-
-
Stam, K.1
Heisterkamp, N.2
Grosveld, G.3
-
12
-
-
0025187837
-
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
-
Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87(17):6649-6653.
-
(1990)
Proc Natl Acad Sci U S A
, vol.87
, Issue.17
, pp. 6649-6653
-
-
Kelliher, M.A.1
McLaughlin, J.2
Witte, O.N.3
Rosenberg, N.4
-
13
-
-
0025117392
-
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
-
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-830.
-
(1990)
Science
, vol.247
, Issue.4944
, pp. 824-830
-
-
Daley, G.Q.1
Van Etten, R.A.2
Baltimore, D.3
-
14
-
-
0025271543
-
Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
-
Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. Embo J. 1990;9(4):1069-1078.
-
(1990)
Embo J
, vol.9
, Issue.4
, pp. 1069-1078
-
-
Elefanty, A.G.1
Hariharan, I.K.2
Cory, S.3
-
15
-
-
38349101871
-
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
-
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
-
(2008)
Leukemia
, vol.22
, Issue.1
, pp. 14-22
-
-
Tefferi, A.1
Vardiman, J.W.2
-
16
-
-
77954581139
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
-
Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
-
(2010)
Leukemia
, vol.24
, Issue.6
, pp. 1128-1138
-
-
Tefferi, A.1
-
17
-
-
84860739723
-
SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients
-
In press
-
Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2011. In press.
-
(2011)
Leukemia
-
-
Lasho, T.L.1
Finke, C.M.2
Hanson, C.A.3
-
18
-
-
79960396947
-
Novel CUX1 missense mutation in association with 7q- At leukemic transformation of MPN
-
Thoennissen NH, Lasho T, Thoennissen GB, Ogawa S, Tefferi A, Koeffler HP. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol. 2011;86(8):703-705.
-
(2011)
Am J Hematol
, vol.86
, Issue.8
, pp. 703-705
-
-
Thoennissen, N.H.1
Lasho, T.2
Thoennissen, G.B.3
Ogawa, S.4
Tefferi, A.5
Koeffler, H.P.6
-
19
-
-
79960248721
-
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
-
Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011;25(7):1219-1220.
-
(2011)
Leukemia
, vol.25
, Issue.7
, pp. 1219-1220
-
-
Abdel-Wahab, O.1
Pardanani, A.2
Rampal, R.3
Lasho, T.L.4
Levine, R.L.5
Tefferi, A.6
-
20
-
-
34548042964
-
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel
-
DOI 10.1182/blood-2007-04-083501
-
Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
-
(2007)
Blood
, vol.110
, Issue.4
, pp. 1092-1097
-
-
Tefferi, A.1
Thiele, J.2
Orazi, A.3
Kvasnicka, H.M.4
Barbui, T.5
Hanson, C.A.6
Barosi, G.7
Verstovsek, S.8
Birgegard, G.9
Mesa, R.10
Reilly, J.T.11
Gisslinger, H.12
Vannucchi, A.M.13
Cervantes, F.14
Finazzi, G.15
Hoffman, R.16
Gilliland, D.G.17
Bloomfield, C.D.18
Vardiman, J.W.19
-
21
-
-
79952087335
-
DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
-
Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
-
(2011)
J Clin Oncol
, vol.29
, Issue.4
, pp. 392-397
-
-
Gangat, N.1
Caramazza, D.2
Vaidya, R.3
-
22
-
-
79953711716
-
How I treat myelofibrosis
-
Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494-3504.
-
(2011)
Blood
, vol.117
, Issue.13
, pp. 3494-3504
-
-
Tefferi, A.1
-
24
-
-
77956696835
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
-
Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
-
(2010)
N Engl J Med
, vol.363
, Issue.12
, pp. 1117-1127
-
-
Verstovsek, S.1
Kantarjian, H.2
Mesa, R.A.3
-
25
-
-
79952333359
-
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
-
Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-796.
-
(2011)
J Clin Oncol
, vol.29
, Issue.7
, pp. 789-796
-
-
Pardanani, A.1
Gotlib, J.R.2
Jamieson, C.3
-
26
-
-
42449124578
-
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
-
DOI 10.1038/sj.leu.2405097, PII 2405097
-
Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756-761. (Pubitemid 351559282)
-
(2008)
Leukemia
, vol.22
, Issue.4
, pp. 756-761
-
-
Tefferi, A.1
Lasho, T.L.2
Huang, J.3
Finke, C.4
Mesa, R.A.5
Li, C.Y.6
Wu, W.7
Hanson, C.A.8
Pardanani, A.9
-
27
-
-
33750534561
-
MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients
-
Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
-
(2006)
Blood
, vol.108
, Issue.10
, pp. 3472-3476
-
-
Pardanani, A.D.1
Levine, R.L.2
Lasho, T.3
-
28
-
-
67349145955
-
Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates
-
Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900-904.
-
(2009)
Leukemia
, vol.23
, Issue.5
, pp. 900-904
-
-
Tefferi, A.1
Levine, R.L.2
Lim, K.H.3
-
29
-
-
74249123815
-
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
-
Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24(1):105-109.
-
(2010)
Leukemia
, vol.24
, Issue.1
, pp. 105-109
-
-
Tefferi, A.1
Lasho, T.L.2
Patnaik, M.M.3
-
30
-
-
77954658823
-
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
-
Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302-1309.
-
(2010)
Leukemia
, vol.24
, Issue.7
, pp. 1302-1309
-
-
Tefferi, A.1
Lasho, T.L.2
Abdel-Wahab, O.3
-
31
-
-
78651344350
-
Refined cytogeneticrisk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients
-
Caramazza D, Begna KH, Gangat N, et al. Refined cytogeneticrisk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82-88.
-
(2011)
Leukemia
, vol.25
, Issue.1
, pp. 82-88
-
-
Caramazza, D.1
Begna, K.H.2
Gangat, N.3
-
32
-
-
63849328927
-
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
-
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
-
(2009)
Blood
, vol.113
, Issue.13
, pp. 2895-2901
-
-
Cervantes, F.1
Dupriez, B.2
Pereira, A.3
-
33
-
-
77950352432
-
A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
-
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
-
(2010)
Blood
, vol.115
, Issue.9
, pp. 1703-1708
-
-
Passamonti, F.1
Cervantes, F.2
Vannucchi, A.M.3
-
34
-
-
0032916213
-
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An olmsted county study, 1976-1995
-
DOI 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I
-
Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61(1):10-15. (Pubitemid 29218171)
-
(1999)
American Journal of Hematology
, vol.61
, Issue.1
, pp. 10-15
-
-
Mesa, R.A.1
Silverstein, M.N.2
Jacobsen, S.J.3
Wollan, P.C.4
Tefferi, A.5
-
35
-
-
80054028202
-
Long-term outcome of ruxolitinib therapy in myelofibrosis
-
Tefferi A, Litzow MR, Pardanani A. Long-term outcome of ruxolitinib therapy in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
-
(2011)
N Engl J Med
, vol.365
, Issue.15
, pp. 1455-1457
-
-
Tefferi, A.1
Litzow, M.R.2
Pardanani, A.3
-
36
-
-
84900620388
-
Long-term outcome of pomalidomide therapy in myelofibrosis
-
In press
-
Begna KH, Pardanani A, Mesa RA, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Blood. 2011. In press.
-
(2011)
Blood
-
-
Begna, K.H.1
Pardanani, A.2
Mesa, R.A.3
-
37
-
-
71949121402
-
Pomalidomide is active in the treatment of anemia associated with myelofibrosis
-
Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563-4569.
-
(2009)
J Clin Oncol
, vol.27
, Issue.27
, pp. 4563-4569
-
-
Tefferi, A.1
Verstovsek, S.2
Barosi, G.3
-
38
-
-
79751528798
-
A phase-2 trial of low-dose pomalidomide in myelofibrosis
-
Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301-304.
-
(2011)
Leukemia
, vol.25
, Issue.2
, pp. 301-304
-
-
Begna, K.H.1
Mesa, R.A.2
Pardanani, A.3
-
39
-
-
15644380236
-
Long-term survival of patients with acute myeloid leukemia: A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia
-
Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80(11, suppl):2191-2198.
-
(1997)
Cancer
, vol.80
, Issue.11 SUPPL.
, pp. 2191-2198
-
-
Bloomfield, C.D.1
Shuma, C.2
Regal, L.3
-
40
-
-
0030897009
-
International scoring system for evaluating prognosis in myelodysplastic syndromes
-
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
-
(1997)
Blood
, vol.89
, Issue.6
, pp. 2079-2088
-
-
Greenberg, P.1
Cox, C.2
LeBeau, M.M.3
Fenaux, P.4
Morel, P.5
Sanz, G.6
Sanz, M.7
Vallespi, T.8
Hamblin, T.9
Oscier, D.10
Ohyashiki, K.11
Toyama, K.12
Aul, C.13
Mufti, G.14
Bennett, J.15
-
41
-
-
80055075486
-
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically-annotated patients
-
Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically-annotated patients. Blood. 2011;118(17):4595-4598.
-
(2011)
Blood
, vol.118
, Issue.17
, pp. 4595-4598
-
-
Tefferi, A.1
Jimma, T.2
Gangat, N.3
-
42
-
-
79957625402
-
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
-
Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117(21):5612-5615.
-
(2011)
Blood
, vol.117
, Issue.21
, pp. 5612-5615
-
-
Vaidya, R.1
Caramazza, D.2
Begna, K.H.3
-
43
-
-
77449126735
-
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
-
Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115(3):496-499.
-
(2010)
Blood
, vol.115
, Issue.3
, pp. 496-499
-
-
Hussein, K.1
Pardanani, A.D.2
Van Dyke, D.L.3
Hanson, C.A.4
Tefferi, A.5
-
44
-
-
61349116698
-
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
-
Hussein K, Huang J, Lasho T, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009;82(4):255-259.
-
(2009)
Eur J Haematol
, vol.82
, Issue.4
, pp. 255-259
-
-
Hussein, K.1
Huang, J.2
Lasho, T.3
-
45
-
-
34248340834
-
Validation and comparison of contemporary prognostic models in primary myelofibrosis: Analysis based on 334 patients from a single institution
-
DOI 10.1002/cncr.22630
-
Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083-2088. (Pubitemid 46744203)
-
(2007)
Cancer
, vol.109
, Issue.10
, pp. 2083-2088
-
-
Tefferi, A.1
Huang, J.2
Schwager, S.3
Li, C.-Y.4
Wu, W.5
Pardanani, A.6
Mesa, R.A.7
-
46
-
-
74049116496
-
Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
-
Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010;84(2):105-108.
-
(2010)
Eur J Haematol
, vol.84
, Issue.2
, pp. 105-108
-
-
Patnaik, M.M.1
Caramazza, D.2
Gangat, N.3
Hanson, C.A.4
Pardanani, A.5
Tefferi, A.6
-
47
-
-
65649110882
-
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis - Increased serum ferritin or transfusion load does not
-
Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis - increased serum ferritin or transfusion load does not. Am J Hematol. 2009;84(5):265-267.
-
(2009)
Am J Hematol
, vol.84
, Issue.5
, pp. 265-267
-
-
Tefferi, A.1
Mesa, R.A.2
Pardanani, A.3
-
48
-
-
81055126771
-
EZH2 mutational status predicts poor survival in myelofibrosis
-
Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227-5234.
-
(2011)
Blood
, vol.118
, Issue.19
, pp. 5227-5234
-
-
Guglielmelli, P.1
Biamonte, F.2
Score, J.3
-
49
-
-
84857993923
-
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F
-
In press
-
Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2011. In press.
-
(2011)
Leukemia
-
-
Tefferi, A.1
Jimma, T.2
Sulai, N.H.3
-
50
-
-
79954433836
-
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study
-
Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
-
(2011)
J Clin Oncol
, vol.29
, Issue.10
, pp. 1356-1363
-
-
Tefferi, A.1
Vaidya, R.2
Caramazza, D.3
Finke, C.4
Lasho, T.5
Pardanani, A.6
-
51
-
-
84900645349
-
IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
-
In press
-
Pardanani A, Finke C, Lasho TL, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2011. In press.
-
(2011)
Leukemia
-
-
Pardanani, A.1
Finke, C.2
Lasho, T.L.3
-
52
-
-
79953045011
-
Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis
-
Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol. 2011;86(4):343-345.
-
(2011)
Am J Hematol
, vol.86
, Issue.4
, pp. 343-345
-
-
Pardanani, A.1
Begna, K.2
Finke, C.3
Lasho, T.4
Tefferi, A.5
-
53
-
-
79751531643
-
Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype
-
Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2011;25(2):266-270.
-
(2011)
Leukemia
, vol.25
, Issue.2
, pp. 266-270
-
-
Patnaik, M.M.1
Hanson, C.A.2
Hodnefield, J.M.3
Knudson, R.4
Van Dyke, D.L.5
Tefferi, A.6
|